This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer

This study has been completed.
OSI Pharmaceuticals
Information provided by (Responsible Party):
Astellas Pharma Inc Identifier:
First received: October 3, 2002
Last updated: October 18, 2011
Last verified: October 2011
The purpose of this study is to determine whether OSI-211 (Liposomal Lurtotecan) is an effective and safe treatment for patients with recurrent small cell lung cancer.

Condition Intervention Phase
SCLC Carcinoma, Small Cell Drug: OSI-211 (Liposomal Lurtotecan) Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study to Determine the Efficacy of OSI-211 (Liposomal Lurtotecan) Given on Days 1, 2 & 3 Every 3 Weeks in Patients With Recurrent Small Cell Lung Cancer

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:

Estimated Enrollment: 47
Study Start Date: September 2002
Study Completion Date: February 2003

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed recurrent small cell lung cancer.
  • One prior treatment of chemotherapy.
  • At least three weeks since last chemotherapy treatment and recovery from any related side effects.
  • At least three weeks since last chest radiotherapy and at least 10 days since head irradiation and recovery from acute side effects.
  • At least one target tumor less than or equal to 20 mm (or less than or equal to 10 mm on spiral CT-scan).
  • If a patient has had previous documented Central Nervous System (CNS) involvement, only controlled disease is acceptable.

Exclusion Criteria:

  • Superior vena cava syndrome.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00046787

United States, Arizona
Arizona Clinical Research Center, Inc.
Tucson, Arizona, United States, 85712
United States, Colorado
University of Colorado Health Sciences Center
Denver, Colorado, United States, 80262
United States, Tennessee
Baptist Hospital Regional Cancer Ctr.
Knoxville, Tennessee, United States, 37920
Vanderbilt Clinical Trials Office
Nashville, Tennessee, United States, 37232-6307
United Kingdom
Nottingham City Hospital
Nottingham, Nottinghamshire, United Kingdom, NG5 1PB
Clatterbridge Centre for Oncology
Bebington, Wirral, United Kingdom, CH63 4JY
Aberdeen Royal Infirmary
Aberdeen, United Kingdom
Guys Hospital
London, United Kingdom, SE1
Christie Hospital
Manchester, United Kingdom, M20 9BH
Northern Centre for Cancer Research, Newcastle General Hospital
Newcastle-upon-Tyne, United Kingdom, NE4 6BE
Sponsors and Collaborators
Astellas Pharma Inc
OSI Pharmaceuticals
  More Information

Responsible Party: Astellas Pharma Inc Identifier: NCT00046787     History of Changes
Other Study ID Numbers: 110-12
Study First Received: October 3, 2002
Last Updated: October 18, 2011

Keywords provided by Astellas Pharma Inc:
Small Cell Lung Cancer

Additional relevant MeSH terms:
Carcinoma, Small Cell
Lung Neoplasms
Small Cell Lung Carcinoma
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 19, 2017